Together, these findings reaffirm the proposed temporal relationship between tau pathology and cognitive decline [46] and establish the potential of tau PET for identifying AD patients in clinical practice who are at risk for more rapid cognitive decline and for stratification and/or enrichment of participant selection in therapeutic clinical trials in AD. The gene discussed is MAPT; the disease is Mental deterioration.